Fintel reports that on October 7, 2026, Barclays initiated coverage of Edwards Lifesciences (NYSE:EW) (SWX:EW) with a Overweight recommendation.Edwards Lifesciences Corporation, based in the United States, operates primarily in the healthcare sector, focusing on the development a

Barclays Initiates Coverage of Edwards Lifesciences at Overweight

(RTTNews) - The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic deals and corporate activity. Key updates spanned oncology, rare diseases, cardiov

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data 

(RTTNews) - Edwards Lifesciences (EW) announced that the U.S. FDA has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed for pediatric patients with congenital heart disease who require pulmonary valve replacement.

Edwards Secures FDA Approval For First Adjustable Pulmonary Valve For Children 

(RTTNews) - Thursday, Edwards Lifesciences (EW) announced that the U.S. FDA approved the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease.

Edwards Wins FDA Approval For First Pediatric Surgical Pulmonary Valve 

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth pl

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead

Insider reported a trade at Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporation News